MedTrace Logo

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

NCT01895543 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2016-05-09

Study results available
· View outcomes & findings →

Summary

Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)

Conditions

  • Chronic Idiopathic Constipation

Interventions

DRUG

Elobixibat 10 mg

10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • Hungary
  • Poland
  • Slovakia
  • South Africa
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01895543 on ClinicalTrials.gov